ArcticZymes Technologies ASA - Special Call Transcript
Okay. It's 8:30, so I suggest we start. So good morning, and welcome to the Q&A session regarding the announcement we made yesterday about divesting the Biotec BetaGlucans business to Lallemand's subsidiary, Danstar Ferment AG.
What we'd like to do today is use today to answer questions that you may have related to the announcement. We know it's some time until the Q4 announcement hence, where we thought it was timely to have a dedicated Q&A session today about the divestment.
So basically, it'd be myself, Jethro Holter, the CEO, who will answer questions and Børge would also help. Børge Sørvoll, our CFO, will also support. We'll be answering questions here as well.
But before we go into questions, I'd like to give you a little brief background about the divestment. And let's wind the clock back to December last year. It's important to understand the strategy here. So back in December last year, we made some strategic decisions. And what we said is we were going to maintain ArcticZymes Technology or Biotec Pharmacon
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
